Davood KHoda Amorzideh on VTE and Bleeding in Cancer
Davood KHoda Amorzideh, Clinical Cardiologist at Farjam Heart Clinic, shared on LinkedIn:
”In the AVERT post-hoc analysis, cancer patients at intermediate-high VTE risk (Khorana_score ≥2) with elevated baseline GDF_15 had increased VTE risk, while elevated NT proBNP and CRP levels predicted bleeding.
Increasing hs-TnT levels from baseline to 1 month was associated with increased VTE risk.
Steven Hawken, Marc Carrier, Philip Wells, Dylan Burger, Tzu-Fei Wang’‘
Read the full article here.
Article: Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers Open Access
Authors: Danielle Carole Roy , Tzu-Fei Wang , Ranjeeta Mallick , Dylan Burger , Marc Carrier , Philip Wells , Steven Hawken
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria